4 aprile 2025|
AI
|8 months agoSwiss Gene Therapy Sector Faces Critical Moment
Analysis of challenges and opportunities in Switzerland's gene therapy industry amid global setbacks
AI
Generated IllustrationKey Takeaways
AI
- Investments in cell and gene therapy dropped below $13 billion in 2022 and 2023.
- Small gene therapy makers have slashed workforces, collapsed, or abandoned markets due to a cash crunch.
- Swiss pharmaceutical giants Roche and Novartis continue to invest in gene therapy despite industry-wide challenges.
- Investment levels showed a slight improvement in 2024 following positive approvals and increased clinical trials in Europe.
By The Numbers
$19.9 billion
Global investment in cell and gene therapy in 2020
CHF 2.7 million
Price of Hemgenix per patient
1 in 2,000
Prevalence of some rare diseases
They Said
"When one drug does well, people think that weâve already won, that weâve figured it out. Despite remarkable outcomes from some gene therapies, there are still improvements needed."
1
The Great Capital Crash
2
Swiss Titans Hold the Line
3
The Multi-Million Franc Cure
4